Long-term Etanercept Response for Patients with Radiographic Axial Spondyloarthritis Based on Achievement of Early, Intermediate, or Late Responses During Index Studies

Xenofon Baraliakos,Annette E. Szumski,Kenneth K. Kwok,Bonnie Vlahos,Cecilia E. Borlenghi

DOI: https://doi.org/10.1007/s40744-024-00656-3

2024-03-15

Rheumatology and Therapy

Abstract:IntroductionShort-term placebo (PBO)- or active-controlled clinical studies have demonstrated that etanercept (ETN) is effective and well tolerated in patients with radiographic axial spondyloarthritis (r-axSpA) with long-term efficacy and safety continuing for up to 7 years after treatment start. Short-term randomized controlled trials (RCTs) have shown the efficacy of ETN after 12–24 weeks, with statistically significant improvements as early as week 2. This post hoc analysis investigated the timeframe (i.e., temporal responses) in which patients with r-axSpA achieved their first clinical response with ETN and how patients responded over a longer period according to different temporal responses in index studies.MethodsData were analyzed from three phase 3/4 PBO- or sulfasalazine-controlled RCTs of ETN for the treatment of r-axSpA (index studies). Long-term open-label extension (OLE) studies assessed how patients responded over a longer period according to different temporal responses (“Early,” “Intermediate,” “Late,” or “Non-response”) in their corresponding index studies.ResultsWithin each index study, patient responses differed significantly between ETN and control arms for achievement of Assessment in SpondyloArthritis international Society (ASAS) 20 and other measures of treatment response. In general, the proportion of responders in the OLE studies was high for those with “Early” and “Intermediate” responses as defined in the index studies. Despite patients being considered non-responders in the index studies, a large proportion achieved response on continued treatment in the OLE studies over the longer term, including through 48 weeks.ConclusionsResponse in the index studies was maintained in the long term, and continued treatment was warranted in a large proportion of patients despite initial non-response. Absence of an early response in index studies did not predict non-response over the long term, and early response to treatment was not always a predictor for later response.Trial RegistrationNCT00421915; NCT00247962; NCT00356356; NCT00421980; NCT00410046.

rheumatology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the time frames of early, intermediate, or late responses in patients receiving etanercept (ETN) for the treatment of radiographic axial spondyloarthritis (r - axSpA), and to explore the response situations of patients with these different time - based responses in the long - term open - label extension (OLE) study. Specifically, the study aims to:

1. **Explore the time frame**: Determine the time point at which patients achieve their first clinical response when treated with ETN, namely early response (Early), intermediate response (Intermediate), late response (Late), or non - response (Non - response).
2. **Long - term response analysis**: Evaluate the response situations of patients with different time - based responses in the initial short - term study over a longer period through the OLE study, especially whether patients regarded as non - responders in the initial study can respond after long - term treatment.
3. **Predict long - term outcomes**: Explore whether early response can predict long - term favorable outcomes, and whether the lack of early response means that long - term treatment is ineffective.

Through these analyses, the study hopes to provide more scientific basis for treatment decisions in patients with r - axSpA, especially for those who do not show obvious effects in the initial treatment, whether they should continue to receive ETN treatment.